PreveCeutical Medical Inc. (PRVCF)
USD 0.02
(6.38%)
USD 0.02
(6.38%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -905.47 Thousand CAD | 16.76% |
| 2022 | -1.02 Million CAD | -21.84% |
| 2021 | -829.83 Thousand CAD | 56.77% |
| 2020 | -2.06 Million CAD | 38.04% |
| 2019 | -2.83 Million CAD | 60.65% |
| 2018 | -11.33 Million CAD | -82.91% |
| 2017 | -7.05 Million CAD | -71.23% |
| 2016 | -3.1 Million CAD | -4230.13% |
| 2015 | - CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -139.61 Thousand CAD | 59.05% |
| 2024 Q2 | -273.02 Thousand CAD | -98.78% |
| 2023 Q2 | -160.08 Thousand CAD | 45.22% |
| 2023 Q3 | -150.68 Thousand CAD | 5.87% |
| 2023 Q1 | -292.25 Thousand CAD | -12.05% |
| 2023 Q4 | -350.25 Thousand CAD | -132.44% |
| 2023 FY | - CAD | 12.36% |
| 2022 Q1 | -159.93 Thousand CAD | 44.59% |
| 2022 FY | - CAD | -21.84% |
| 2022 Q4 | -260.81 Thousand CAD | 47.24% |
| 2022 Q3 | -494.31 Thousand CAD | -186.26% |
| 2022 Q2 | -172.68 Thousand CAD | -7.97% |
| 2021 Q1 | -375.84 Thousand CAD | 75.58% |
| 2021 Q4 | -288.66 Thousand CAD | -425.94% |
| 2021 Q3 | 88.56 Thousand CAD | 127.95% |
| 2021 Q2 | -316.81 Thousand CAD | 15.71% |
| 2021 FY | - CAD | 56.77% |
| 2020 Q1 | -237.66 Thousand CAD | -1293.71% |
| 2020 Q3 | 422.63 Thousand CAD | 159.42% |
| 2020 Q4 | -1.53 Million CAD | -464.09% |
| 2020 FY | - CAD | 38.04% |
| 2020 Q2 | -711.23 Thousand CAD | -199.26% |
| 2019 Q2 | -1.47 Million CAD | -46.0% |
| 2019 Q4 | 19.91 Thousand CAD | 102.32% |
| 2019 Q3 | -859.74 Thousand CAD | 41.89% |
| 2019 FY | - CAD | 60.65% |
| 2019 Q1 | -1.01 Million CAD | 58.45% |
| 2018 Q1 | -1.4 Million CAD | 43.71% |
| 2018 FY | - CAD | -82.91% |
| 2018 Q2 | -1.91 Million CAD | -36.31% |
| 2018 Q3 | -2.54 Million CAD | -33.13% |
| 2018 Q4 | -2.43 Million CAD | 4.32% |
| 2017 Q3 | -1.12 Million CAD | -68.31% |
| 2017 FY | - CAD | -71.23% |
| 2017 Q1 | -94.55 Thousand CAD | 20.86% |
| 2017 Q2 | -668.42 Thousand CAD | -606.91% |
| 2017 Q4 | -2.49 Million CAD | -121.84% |
| 2016 Q3 | -106.02 Thousand CAD | -297.5% |
| 2016 FY | - CAD | -4230.13% |
| 2016 Q1 | -32.29 Thousand CAD | -90.42% |
| 2016 Q4 | -119.47 Thousand CAD | -12.69% |
| 2016 Q2 | -26.67 Thousand CAD | 17.41% |
| 2015 FY | - CAD | 0.0% |
| 2015 Q3 | -1704.00 CAD | 0.0% |
| 2015 Q4 | -16.96 Thousand CAD | -895.36% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 98.725% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 84.728% |
| SQZ Biotechnologies Company | -64.14 Million USD | 98.588% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 94.787% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 100.963% |
| Mesoblast Limited | -62.38 Million USD | 98.549% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 41.052% |
| Genus plc | 73.7 Million USD | 101.229% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 86.305% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 74.472% |
| Marizyme, Inc. | -34.28 Million USD | 97.359% |
| ContraFect Corporation | -64.99 Million USD | 98.607% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 89.678% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 79.995% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 35.407% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 65.759% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 61.035% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -74.787% |
| Accustem Sciences Inc. | -3.74 Million USD | 75.831% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 98.122% |
| EV Biologics, Inc. | -1.26 Million USD | 28.541% |
| Q BioMed Inc. | -617.62 Thousand USD | -46.605% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 125.349% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -43.179% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 60.364% |
| Biomind Labs Inc. | -1.03 Million USD | 12.476% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 109.168% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 87.356% |
| Skye Bioscience, Inc. | -13.54 Million USD | 93.316% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 39.124% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -3521.9% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 76.689% |
| IMV Inc. | -35.52 Million USD | 97.451% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 94.294% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 63.809% |
| GB Sciences, Inc. | -1.41 Million USD | 36.229% |
| Alpha Cognition Inc. | -9.7 Million USD | 90.671% |
| HST Global, Inc. | -5303.00 USD | -16974.769% |
| CSL Limited | 4.78 Billion USD | 100.019% |
| Halberd Corporation | -74.27 Thousand USD | -1119.019% |
| Enzolytics Inc. | -2.12 Million USD | 57.33% |
| Resverlogix Corp. | -11.74 Million USD | 92.289% |
| Affymax, Inc. | -14.29 Million USD | 93.666% |
| SYBLEU INC | -141.57 Thousand USD | -539.591% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 70.438% |
| argenx SE | -216.02 Million USD | 99.581% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 98.364% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 174.402% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 39.591% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 339.01% |
| AVAX Technologies, Inc. | -6.11 Million USD | 85.187% |
| Zenith Capital Corp. | -8.6 Million USD | 89.479% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.636% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -5097.606% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 62.988% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -414.403% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 97.716% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 68.694% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 13.46% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 13566.315% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 48.259% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 52.862% |
| BioStem Technologies, Inc. | -7.55 Million USD | 88.013% |
| ONE Bio Corp. | 13.61 Million USD | 106.652% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -400.019% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 55.981% |
| Agentix Corp. | -1.37 Million USD | 33.992% |
| LadRx Corporation | 412.28 Thousand USD | 319.625% |
| Cell Source, Inc. | -4.27 Million USD | 78.807% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -146.575% |
| Regen BioPharma, Inc. | 1.46 Million USD | 161.767% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 3.359% |
| NovAccess Global Inc. | -1.03 Million USD | 12.497% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 110.227% |
| Itoco Inc. | -1.86 Million USD | 51.553% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -138.521% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 18.864% |
| Kadimastem Ltd | -2.62 Million USD | 65.498% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -278.622% |
| CytoDyn Inc. | -18.02 Million USD | 94.978% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -1045.75% |
| Mobile Lads Corp. | -2.24 Million USD | 59.598% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -7304.326% |
| Qrons Inc. | -40.08 Thousand USD | -2159.113% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -86.435% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 271.676% |
| Rebus Holdings, Inc. | -951 Thousand USD | 4.787% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 14.74% |
| International Stem Cell Corporation | 202 Thousand USD | 548.255% |
| Bioxytran, Inc. | -3.82 Million USD | 76.297% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -1620.127% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 63.221% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 97.476% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -1912.167% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 66.929% |
| Neutra Corp. | -181.24 Thousand USD | -399.581% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 95.508% |
| PureTech Health plc | -11.62 Million USD | 92.212% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 95.508% |
| IXICO plc | -707 Thousand USD | -28.073% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 88.218% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 98.127% |
| CSL Limited | 4.73 Billion USD | 100.019% |
| Cellectis S.A. | -92.63 Million USD | 99.023% |